Comparative Pharmacology
Head-to-head clinical analysis: HEAVY SOLUTION NUPERCAINE versus POLOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEAVY SOLUTION NUPERCAINE versus POLOCAINE.
HEAVY SOLUTION NUPERCAINE vs POLOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heavy solution nupercaine (dibucaine) is a potent, long-acting amide local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the propagation of action potentials and preventing nerve impulse conduction.
Local anesthetic that stabilizes the neuronal membrane by inhibiting the influx of sodium ions, thereby blocking nerve impulse propagation.
Spinal anesthesia: 0.5-1 mL of 0.5% heavy solution (2.5-5 mg) injected intrathecally; dose depends on level of anesthesia required.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life is 2.5-4 hours (mean 3.5 h) in adults. In neonates, half-life is prolonged (up to 8-12 h) due to immature hepatic function.
Terminal elimination half-life approximately 1.5-2.0 hours in adults; prolonged to 3-5 hours in hepatic impairment and neonates.
Primarily hepatic metabolism to inactive metabolites; renal excretion of unchanged drug accounts for approximately 1-5%. Biliary excretion is minimal (<5%). Total fecal elimination is negligible (<1%).
Hepatic metabolism to 2,6-xylidine and 4-hydroxy-2,6-xylidine; <10% excreted unchanged in urine; approximately 70-80% of metabolites excreted renally, with <5% in feces.
Category C
Category C
Local Anesthetic
Local Anesthetic